...
首页> 外文期刊>Alcohol and Alcoholism >COMBINED ACAMPROSATE AND NALTREXONE, WITH COGNITIVE BEHAVIOURAL THERAPY IS SUPERIOR TO EITHER MEDICATION ALONE FOR ALCOHOL ABSTINENCE: A SINGLE CENTRES' EXPERIENCE WITH PHARMACOTHERAPY
【24h】

COMBINED ACAMPROSATE AND NALTREXONE, WITH COGNITIVE BEHAVIOURAL THERAPY IS SUPERIOR TO EITHER MEDICATION ALONE FOR ALCOHOL ABSTINENCE: A SINGLE CENTRES' EXPERIENCE WITH PHARMACOTHERAPY

机译:联合使用苯甲酸酯和纳曲酮,进行认知行为治疗优于单独使用酒精药物的药物:单中心的药物治疗经验

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either naltrexone or acamprosate used singly or in combination, in a 12-week outpatient cognitive behavioural therapy (CBT) programme for alcohol dependence. Methods: We matched 236 patients across gender, age group, prior alcohol detoxification, and dependence severity and conducted a cohort comparison study of three medication groups (CBT+acamprosate, CBT+naltrexone, CBT+combined medication) which included 59 patients per group. Outcome measures included programme attendance, programme abstinence and for those who relapsed, cumulative abstinence duration (CAD) and days to first breach (DFB). Secondary analyses compared the remaining matched 59 subjects who declined medication with the pharmacotherapy groups. Results: Across medication groups, CBT+ combined medication produced the greatest improvement across all outcome measures. Although a trend favoured the CBT+ combined group, differences did not reach statistical significance. Programme attendance: CBT + Acamprosate group (66.1%), CBT + Naltrexone group (79.7%), and in the CBT + Combined group (83.1%). Abstinence rates were 50.8, 66.1, and 67.8%, respectively. For those that did not complete the programme abstinent, the average number of days abstinent (CAD) were 45.07, 49.95, and 53.58 days, respectively. The average numbers of days to first breach (DFB) was 26.79, 26.7, and 37.32 days. When the focal group (CBT + combined) was compared with patients who declined medication (CBT-alone), significant differences were observed across all outcome indices. Withdrawal due to adverse medication effects was minimal. Conclusions: The addition of both medications (naltrexone and acamprosate) resulted in measurable benefit and was well tolerated. In this patient population naltrexone with CBT is as effective as combined medication with CBT, but the trend favours combination medication.
机译:目的:为了比较在接受酒精依赖的12周门诊认知行为治疗(CBT)计划中,单独或联合使用纳曲酮或阿坎酸的药物治疗患者的治疗效果。方法:我们对236名性别,年龄组,既往酒精戒毒和依赖性严重程度的患者进行了匹配,并对三个药物组(CBT +阿坎酸,CBT +纳曲酮,CBT +联合用药)进行了队列比较研究,每组包括59名患者。结果指标包括计划出勤,计划禁欲和复发者的累积禁忌持续时间(CAD)和首次违约天数(DFB)。次要分析比较了其余匹配的59名拒绝药物治疗的受试者与药物治疗组。结果:在所有药物治疗组中,CBT +联合药物在所有结局指标中均产生最大的改善。尽管趋势倾向于CBT +合并组,但差异未达到统计学意义。参加课程的人数:CBT +阿坎酸酯组(66.1%),CBT +纳曲酮组(79.7%)和CBT +联合组(83.1%)。节制率分别为50.8、66.1和67.8%。对于那些没有完成该计划的人,平均(CAD)天数分别为45.07、49.95和53.58天。首次违反(DFB)的平均天数为26.79、26.7和37.32天。当将焦点小组(CBT +合并)与拒绝药物治疗的患者(单独使用CBT)进行比较时,在所有结局指标上均观察到显着差异。因药物不良反应而停药的可能性很小。结论:两种药物(纳曲酮和阿坎酸)的同时使用均可带来可衡量的益处,并且耐受性良好。在该患者人群中,纳曲酮与CBT的疗效与CBT联合用药一样有效,但是趋势倾向于联合用药。

著录项

  • 来源
    《Alcohol and Alcoholism》 |2006年第3期|321-327|共7页
  • 作者单位

    Alcohol and Drug Assessment Unit Princess Alexandra Hospital Brisbane Queensland 4102 Australia;

    Department of Psychiatry The University of Queensland Brisbane Queensland 4102 Australia;

    School of Psychology and Counselling Faculty of Health Queensland University of Technology Queensland 4034 Australia.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号